GOTHENBURG, SE / ACCESSWIRE / October 7, 2021 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)
Invitation to attend XVIVO’s conference call regarding the presentation of the interim report July – September 2021. The presentation will be held in English.
Time: Thursday, October 21, 2021 at 2.00 p.m. CET
Information regarding the conference can be found under the following link:
https://onlinexperiences.com/Launch/QReg/ShowUUID=07001B8B-3391-4BA9-8F3E-BBE54EDF834E .
Phone numbers to the conference:
Sweden: +46 856642651 PIN: 13466713#
UK: +44 3333000804 PIN: 13466713#
US: +1 6319131422 PIN: 13466713#
Conference name: XVIVO Group Interim Report Q3, conference ID: EV00128347
Participants from XVIVO:
Dag Andersson, CEO
Kristoffer Nordström, CFO
The press release for XVIVO’s interim report July-September 2021 will be released on October 21, 2021 at 7:30 a.m. CET.
Before the conference call, slides will be available at the company web page, https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/
October 7, 2021
Gothenburg
XVIVO Perfusion AB (publ)
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
Attachments
Conference call on Interim Report
SOURCE: XVIVO Perfusion AB
View source version on accesswire.com:
https://www.accesswire.com/667197/Conference-Call-on-Interim-Report
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…
Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…